Substituted Bicyclic Compounds Inhibit HBV Nucleocapsid Assembly
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic hepatitis B and hepatitis D infections are limited, with existing therapies often requiring long-term administration, causing severe side effects, and being ineffective against drug-resistant viruses, and there is a lack of effective antiviral therapies for acute or chronic hepatitis D.
Innovation Solution
Development of substituted bicyclic compounds that inhibit HBV and HDV nucleocapsid assembly, which can be used alone or in combination with DNA polymerase inhibitors to treat and prevent hepatitis B and D infections, including in patients with drug-resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current approved drugs (alpha-interferon, nucleoside/nucleotide analogues) are used to treat chronic hepatitis B, then HBV DNA polymerase inhibition is achieved, but long-term administration is required and drug resistance emerges
Solution Approach 1:
The patent segments the viral replication process into two distinct targets: pgRNA encapsidation (by bicyclic compounds) and DNA polymerase activity (by nucleoside/nucleotide analogues). This segmentation allows combination therapy to attack the virus through multiple independent mechanisms, preventing resistance development while potentially shortening treatment duration.
Solution Approach 2:
The patent employs a composite therapeutic approach combining two different chemical compound classes (bicyclic compounds and nucleoside/nucleotide analogues) with distinct mechanisms of action. This composite strategy addresses both the effectiveness and duration issues by creating synergistic antiviral activity that prevents resistance emergence.
2Reliability
If peg-interferon alfa-2a is used to treat chronic hepatitis B, then serological milestones are achieved in one third of patients, but severe side effects occur
Solution Approach 1:
The bicyclic compounds act as intermediary agents that specifically target pgRNA encapsidation without triggering the severe immune-mediated side effects associated with interferon therapy. This intermediary mechanism achieves antiviral efficacy through a different biological pathway, avoiding the harmful factors of interferon while maintaining treatment effectiveness.
Solution Approach 2:
The patent substitutes the immune-modulating mechanism of interferon (which causes severe side effects) with a direct enzymatic inhibition mechanism (bicyclic compounds blocking pgRNA encapsidation). This substitution replaces a complex immune system interaction with a more specific molecular target, reducing harmful effects while maintaining antiviral activity.
3Reliability
If nucleoside/nucleotide analogues are used to treat chronic hepatitis B, then HBV replication is suppressed, but drug-resistant viruses emerge requiring lifetime administration
Solution Approach 1:
The patent segments the antiviral strategy into two independent mechanisms: pgRNA encapsidation inhibition (bicyclic compounds) and DNA polymerase inhibition (nucleoside/nucleotide analogues). This segmentation creates a barrier to resistance because simultaneous mutations in both targets are statistically unlikely, allowing shorter treatment durations while maintaining suppression effectiveness.
Solution Approach 2:
The bicyclic compounds provide a universal antiviral mechanism that targets an early step in the viral lifecycle (pgRNA encapsidation) independent of DNA polymerase function. This multi-functional approach ensures that resistance to one agent does not confer resistance to the other, addressing the adaptability issue of drug-resistant viruses.
4Reliability
If interferon-alfa is used to treat hepatitis D, then limited response is achieved with only one-quarter of patients having undetectable HDV RNA, but it is the only licensed treatment
Solution Approach 1:
The bicyclic compounds serve as intermediary therapeutic agents that target a fundamental step in HDV replication (nucleocapsid assembly) without relying on the interferon pathway. This intermediary mechanism provides a new treatment option with potentially higher efficacy, addressing both the response rate limitation and the lack of treatment versatility for hepatitis D.
Solution Approach 2:
The patent changes the therapeutic parameter from immune modulation (interferon) to direct molecular inhibition (bicyclic compounds blocking nucleocapsid assembly). This parameter change creates a fundamentally different treatment approach for hepatitis D, improving response rates and expanding treatment options beyond the single licensed interferon therapy.
Data Source
AI summary
The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) infection in a patient.